<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921712</url>
  </required_header>
  <id_info>
    <org_study_id>601-0010P</org_study_id>
    <nct_id>NCT01921712</nct_id>
  </id_info>
  <brief_title>A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients</brief_title>
  <official_title>A Phase I, 2-Part, Single-dose, Placebo and Active-Controlled, Dose-ranging, Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmatrix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pulmatrix Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of PUR0200. In addition,
      the study will look at the blood levels of different doses of PUR0200 and their affect on
      lung function in COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, 2-part, pharmacokinetic (PK), pharmacodynamic (PD) effect, safety and
      tolerability study of single doses of PUR0200.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of PUR0200</measure>
    <time_frame>0 to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach peak plasma (Tmax) concentration of PUR0200</measure>
    <time_frame>0 to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time (AUC) of PUR0200</measure>
    <time_frame>0 to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1 difference from baseline</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 14 days post-dose</time_frame>
    <description>adverse events, vital signs, clinical laboratory changes, and ECG changes will be evaluated</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>PUR0200 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 low dose, single dose inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0200 mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 mid dose, single dose inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0200 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PUR0200 high dose, single dose inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PUR0200 matched placebo, single dose, inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator, single dose, inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR0200</intervention_name>
    <description>Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator</description>
    <arm_group_label>PUR0200 low dose</arm_group_label>
    <arm_group_label>PUR0200 mid dose</arm_group_label>
    <arm_group_label>PUR0200 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR0200 Placebo</intervention_name>
    <description>Randomized, single dose of inhaled placebo matched to PUR0200</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator</intervention_name>
    <description>Randomized single dose of inhaled active comparator product</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  A clinical diagnosis of moderate to severe COPD according to the following criteria:

               -  Current or ex-smokers with at least 10 pack-year smoking history

               -  Post-bronchodilator FEV1 &gt;/= 35% and &lt;/= 80% of predicted normal value

               -  Post-bronchodilator FEV1/FVC (forced vital capacity) ratio &lt;0.70

               -  Post-bronchodilator improvement in FEV1 &gt;/= 100 mL

        Key Exclusion Criteria:

          -  Current evidence or recent history of clinically significant or unstable disease
             (other than COPD)

          -  Current diagnosis of asthma

          -  Presence of history of clinically significant allergy requiring treatment

          -  COPD exacerbation within 6 weeks

          -  Use of daily oxygen therapy &gt; 10 hours

          -  Thoracotomy with pulmonary resection

          -  Use of systemic steroids within 3 months

          -  Lower respiratory tract infection within 30 days

          -  Upper respiratory tract infection within 30 days requiring treatment with antibiotics

          -  History of tuberculosis, bronchiectasis, or other non-specific pulmonary disease

          -  Prolonged corrected QT (QTc) interval &gt;450 msec males and &gt;470 msec females, or
             history of long QT syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hava, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pulmatrix Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2013</study_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

